Neurogene - NGNE Forward P/S Multiple
The integration of AI into molecular modeling is accelerating drug development at Neurogene Inc. (NGNE). The forward P/S ratio clearly demonstrates the dynamics of market expectations, where the value 325.50 reflects the current figure. Fundamentals rely on the non-cyclical nature of gene therapy and dependence on the FDA, while future pricing power potential is limited by strict government healthcare controls.
Neurogene Therapeutics - analytical breakdowns and key metrics (NGNE)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt and liquidity data:
- net income and valuation multiples indicators:
NGNE - Annual Net Income|Expected Profit Neurogene Inc.|NGNE - Price to Earnings Multiple|Forward P/E Multiple Neurogene Corp|NGNE - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Neurogene Therapeutics|NGNE - Operating profit before amortization|Net earnings per share (EPS TTM) Neurogene|NGNE - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months neurogene.com|NGNE - Earnings growth in current year|Net earnings per share growth forecast for next year Neurogene Inc.
- company sales and revenue statistics:
Analysis of all company metrics:Neurogene (NGNE)
The forward P/S multiple assesses the market value of Neurogene Inc. relative to projected revenue, allowing short-term market noise to be decoupled from the long-term fundamental trend. For Neurogene Inc. (NGNE), the forward P/S multiple trend reflects a market revaluation of gene therapy potential, where high patent values and regulatory barriers determine the asset's long-term investment attractiveness.
Analysis of competing companies
Price-to-Projected Revenue Ratio Biogen BIIB|NBIX: Market Cap to Projected Revenue|Regencell - Forward P/S Multiple|Market Cap to Future Revenue Ratio Axsome Corp|ACAD (ACADIA Pharmaceuticals) - Forward Price-to-Revenue Multiple|xenon-pharma.com - Forward Price to Sales|VKTX (Viking Therapeutics, Inc.) - Forward P/S Multiple|Supernus Pharmaceuticals, Inc. (SUPN) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Catalyst Pharmaceuticals Inc (CPRX)|Denali Corp - Market Cap to Projected Revenue|Forward P/S Multiple HRMY (Harmony Biosciences)|BHVN - Forward Price-to-Revenue Multiple|AMLX: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Trevi Therapeutics Inc TRVI|Praxis Medicines (PRAX) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue AVXL|CBLL (CeriBell, Inc.) - Forward P/S Multiple|PRTA - Projected Price to Revenue|Price-to-Projected Revenue Ratio Alector, Inc. (ALEC)|Annexon Biosciences - Market Cap to Projected Revenue|Forward P/S Multiple OMER (Omeros)|AC Immune Inc (ACIU) - Market Cap to Future Revenue Ratio|VYGR - Price-to-Projected Revenue Ratio|NMRA (neumoratx.com) - Market Cap to Projected Revenue|SCLX: Forward P/S Multiple|Market Cap to Future Revenue Ratio Tevogen Bio Holdings Inc. (TVGN)|Forward Price-to-Revenue Multiple ACOG|Forward P/S Multiple Cognition Therapeutics Inc.|Price-to-Projected Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA (cassavasciences.com) - Forward Price to Sales|Price-to-Projected Revenue Ratio Assertio ASRT|Coya Therapeutics Inc (COYA) - Market Cap to Future Revenue Ratio|VTGN - Price-to-Projected Revenue Ratio|OVID (Ovid Therapeutics Inc.) - Market Cap to Projected Revenue|ABOS: Forward P/S Multiple|Market Cap to Future Revenue Ratio cervomed.com (CRVO)|Forward Price-to-Revenue Multiple ATHE|Forward P/S Multiple Clene Nanomedicine|Price-to-Projected Revenue Ratio PepGen Inc. (PEPG)|JUNS (Jupiter Neurosciences, Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio Relmada Therapeutics RLMD|annovisbio.com (ANVS) - Market Cap to Future Revenue Ratio|Grace Tx - Forward P/S Multiple|Projected Price to Revenue Firefly Neuroscience, Inc. (AIFF)|KLTO: Forward P/S Multiple|Market Cap to Future Revenue Ratio NeuroSense Therapeutics Ltd. (NRSN)|Price-to-Projected Revenue Ratio Reviva Pharmaceuticals|Market Cap to Projected Revenue MTVA (MetaVia, Inc.)|Forward P/S Multiple NRXS|HSDT - Market Cap to Future Revenue Ratio|Passage Bio - Forward Price-to-Revenue Multiple|Forward Price to Sales NEUP|Minerva Neurosciences - Forward P/S Multiple|Market Cap to Expected Sales Ratio athira.com ATHA|Addex Therapeutics Ltd (ADXN) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ALZN|CYCN (Cyclerion Therapeutics Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Protagenic (PTIX)|Forward Price-to-Revenue Multiple KTTA (Pasithea Therapeutics)|Market Cap to Expected Sales Ratio cortigent.com|Price-to-Projected Revenue Ratio Avenue Therapeutics, Inc. ATXI|BCLI: Market Cap to Projected Revenue|Cara Therapeutics, Inc - Forward P/S Multiple|Projected Price to Revenue Chromocell (CHRO)|eliemtx.com (ELYM) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue ITCI|LBPH (Longboard Pharmaceuticals, Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Marinus Pharmaceuticals Inc MRNS|Price-to-Projected Revenue Ratio NKGen (NKGN)|NeuroBo Pharma - Market Cap to Projected Revenue|Forward P/S Multiple SAGE (Sage Therapeutics, Inc.)|synaptogen.com (SNPX) - Market Cap to Future Revenue Ratio|TRVN: Forward Price-to-Revenue Multiple|VIGL - Forward P/S Multiple|Anew Medical (WENA) - Price-to-Projected Revenue Ratio|Cerevel Corp - Forward Price to Sales
